Scinai Immunotherapeutics Shifts Focus to NanoAb and CDMO Growth Strategies

In a significant strategic pivot, Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has announced a refocus of its capital and resources towards its NanoAb platform and its growing contract development and manufacturing organization (CDMO). This decision comes on the heels of concluding option and license agreements with PinCell S.r.l. concerning the development of the PC111 product.

On September 8, 2026, Scinai publicly disclosed that following extensive discussions with PinCell regarding potential agreement extensions, they ultimately reached no further consensus. The expiration of the option conditions on August 31, 2026, led to the termination of the relevant agreements as stipulated.

Despite the termination of these agreements, Scinai's CEO, Amir Reichman, emphasized that this was not a reflection of any adverse scientific findings related to PC111. On the contrary, Scinai remains optimistic about the therapeutic potential of the product and values the collaboration with PinCell. Reichman noted, “PC111 remains an interesting and promising preclinical program,” highlighting the potential that still lies within this project.

Scinai's decision to redirect its focus is fundamentally driven by the company's analysis of where it can derive the most significant value for its shareholders. Advancing preclinical assets like PC111 demands substantial capital and time—resources the company has decided to allocate toward its NanoAb platform, which boasts multiple existing developmental opportunities.

The NanoAb platform harnesses VHH antibody fragments to forge paths in developing therapeutic formats targeting various inflammatory and immune-mediated diseases. Scinai maintains that concentrating efforts on this platform will allow them to best leverage their existing research collaborations, especially with notable institutions like the Max Planck Society and University Medical Center Göttingen.

Rightsizing their portfolio strategy also means Scinai can prioritize projects based on scientific merit, feasibility of development, and the potential to access non-dilutive funding. Scinai currently has two active IL-17 programs within the NanoAb framework. One of these includes an intradermal IL-17 program, aimed at treating psoriasis, which is currently under evaluation for a significant grant intended to support development through early clinical stages.

Furthermore, Scinai continues to engage in expanding its CDMO footprint, having reported approximately $3.1 million in customer orders from its facilities in Jerusalem and Yavne. The company is projecting around $5 million in CDMO revenue for the current year, hinging on successful project execution and relevant timelines.

The ongoing negotiations with a U.S.-based biopharmaceutical customer signal promising growth in this sector, demonstrating Scinai’s capability to execute expanded clinical manufacturing and adhere to chemistry, manufacturing, and controls (CMC) standards. Scinai’s strategic approach aims to enhance customer satisfaction while also bolstering its financial sustainability through operational efficiencies.

In summary, Scinai Immunotherapeutics is poised for a robust transformation, channeling its talents and assets toward innovative therapeutic solutions with its NanoAb platform and simultaneously locking in a rising CDMO business. This dual focus not only mitigates risk by diversifying their R&D investments but also sets the stage for sustainable growth across multiple avenues in the biopharmaceutical landscape. With increasing interest from industry stakeholders and a solid foundation in immunotherapy, Scinai is aiming to build on this refocus to offer greater value to investors and their patients.

For more details on Scinai’s initiatives and developments, visit their official website at www.scinai.com.